Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 285

1.

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.

Lung Cancer. 2004 Dec;46(3):283-91.

PMID:
15541812
[PubMed - indexed for MEDLINE]
2.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.

Mol Cancer Ther. 2003 May;2(5):471-8.

PMID:
12748309
[PubMed - indexed for MEDLINE]
Free Article
3.

Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.

Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE.

Cancer Res. 2001 May 1;61(9):3660-8.

PMID:
11325836
[PubMed - indexed for MEDLINE]
Free Article
4.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.

Clin Cancer Res. 2000 Dec;6(12):4848-58.

PMID:
11156244
[PubMed - indexed for MEDLINE]
Free Article
5.

Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.

Sasaki T, Tanno S, Shibukawa K, Osanai S, Kawabe J, Ohsaki Y.

Int J Oncol. 2008 Sep;33(3):525-32.

PMID:
18695882
[PubMed - indexed for MEDLINE]
6.
7.

Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.

Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL Jr.

Clin Cancer Res. 2004 May 15;10(10):3528-34.

PMID:
15161712
[PubMed - indexed for MEDLINE]
Free Article
8.

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.

Cancer Res. 2006 Sep 1;66(17):8715-21.

PMID:
16951187
[PubMed - indexed for MEDLINE]
Free Article
9.

The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.

Spiekermann K, Faber F, Voswinckel R, Hiddemann W.

Exp Hematol. 2002 Jul;30(7):767-73.

PMID:
12135675
[PubMed - indexed for MEDLINE]
10.

Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.

Loges S, Tinnefeld H, Metzner A, Jücker M, Butzal M, Bruweleit M, Fischer U, Draab E, Schuch G, O'-Farrel AM, Hossfeld DK, Bokemeyer C, Fiedler W.

Leuk Lymphoma. 2006 Dec;47(12):2601-9.

PMID:
17169805
[PubMed - indexed for MEDLINE]
11.

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.

Ning S, Laird D, Cherrington JM, Knox SJ.

Radiat Res. 2002 Jan;157(1):45-51.

PMID:
11754641
[PubMed - indexed for MEDLINE]
12.
13.

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89.

PMID:
15701856
[PubMed - indexed for MEDLINE]
Free Article
14.

Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.

Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE.

Cancer Res. 2003 Dec 15;63(24):8890-8.

PMID:
14695206
[PubMed - indexed for MEDLINE]
Free Article
15.

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.

Clin Cancer Res. 2005 Feb 15;11(4):1563-71.

PMID:
15746061
[PubMed - indexed for MEDLINE]
Free Article
16.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

PMID:
18381963
[PubMed - indexed for MEDLINE]
Free Article
17.

Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.

Donnini S, Monti M, Castagnini C, Solito R, Botta M, Schenone S, Giachetti A, Ziche M.

Int J Cancer. 2007 Mar 1;120(5):995-1004.

PMID:
17131343
[PubMed - indexed for MEDLINE]
18.

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.

Angiogenesis. 2009;12(3):287-96. doi: 10.1007/s10456-009-9151-7. Epub 2009 Jun 21.

PMID:
19544081
[PubMed - indexed for MEDLINE]
19.

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.

Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM.

Blood. 2001 Mar 1;97(5):1413-21.

PMID:
11222388
[PubMed - indexed for MEDLINE]
Free Article
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk